This is the 10th in the series
Contact RN Collins: https://www.linkedin.com/in/rn-collins/
Cannabis Law Report
What three years of licensing data, closures, and unresolved regulatory gaps may suggest about the design of psychedelic service frameworks
I. Introduction: Oregon at Three Years — What the Data May Show
Roughly one in three Oregon psilocybin service centers has closed or surrendered its license as of Q3 2025: 12 of 35 licensed centers, according to the Psychedelic Alpha tracker. That figure alone does not settle the question of whether the program is failing. It is one data point among several, and it is worth reading alongside the rest of the record before drawing conclusions.
The Oregon Health Authority program drew $3.1 million from the state’s general fund to operate during the 2023–25 biennium, and the Legislature allocated no dedicated program funding for 2025–27. OHA appears to be considering an increase to the annual service center license fee, currently $10,000, though the outcome of that consideration is not yet public. Available estimates suggest that up to 80% of Oregon service center clients may be using SSRIs at the time of their session, and the mandatory screening process does not appear to address that interaction risk directly. Senate Bill 303, effective 2025, requires service centers to submit client outcome data to OHA, which creates an administrative record that could, in principle, become discoverable in future civil proceedings, though how courts would treat that record has not been tested.
None of this is offered as a verdict on Oregon’s legal architecture. Oregon’s Measure 109 framework is still, by most accounts, among the most carefully designed psychedelic service structures anywhere, and the closures and funding gaps described above may reflect ordinary market shakeout as much as any defect in the statutory or regulatory design. It may be too early to characterize the program’s early performance as a documented failure. A more cautious reading is that the data reveal real cost pressures and unresolved gaps that regulators in Oregon, and legislators considering similar frameworks elsewhere, may want to examine closely.
This article surveys where the legal architecture and the commercial market appear to diverge, what the record suggests has worked, what has not, and what a next generation of psychedelic service frameworks, in Oregon or elsewhere, might address differently. It does not assume a professional audience taking instruction. It is offered as an analytical account of a developing regulatory space, with a closing set of observations addressed to the regulators and legislators who are positioned to act on them.
II. The Measure 109 Framework in 2026: Legal Architecture, Market Reality
A. The Legal Architecture
Oregon’s Ballot Measure 109, passed by 56% of voters in November 2020, created a non-medical psilocybin services framework under the Oregon Health Authority. The statutory foundation is ORS Chapter 475A. The implementing administrative rules are in OAR Chapter 333-333. The framework covers three license categories: psilocybin service centers (where sessions occur), psilocybin facilitators (who supervise sessions), and psilocybin product manufacturers.
The framework’s organizing principle, explicit in the statute and reinforced throughout the OAR rules, is that psilocybin services are not medical or clinical treatment. ORS § 475A.305 states that a psilocybin service center is not a health care facility subject to ORS Chapter 441. OAR 333-333-1010(72) prohibits use of the term “therapy” in connection with licensed services. OAR 333-333-5130 prohibits facilitators from diagnosing or treating health conditions.
Alongside this explicit non-medical framing, the OAR rules impose obligations that read as clinically informed in character: screening for psychosis and self-harm history (OAR 333-333-5050); recognition of medical emergencies and immediate emergency services contact (OAR 333-333-5120(4)); boundary prohibitions (OAR 333-333-5120(7) and (10)); and a documented standard of care obligation stating that facilitators “have a duty to put clients’ interest above their own and to use a standard of care that other reasonable facilitators would use under similar circumstances.”
This disclaimer-plus-duty structure may be the central legal tension of the Measure 109 framework, and it may also be a significant source of liability exposure for facilitators and service centers, though the extent of that exposure has not been tested in litigation. What seems clear is that this tension was a deliberate regulatory choice, and no court appears to have resolved it. Whether it needs resolving, or functions adequately as ambiguity, is itself an open question.
B. The Market Reality in 2026
As of early 2026, Oregon’s licensed psilocybin service market has experienced what the available data suggest is significant operator attrition. Approximately one-third of licensed service centers, 12 of 35 licensed centers through Q3 2025, had closed or surrendered their licenses. The failure pattern may be recognizable from cannabis: high fixed costs, a thin initial demand pool concentrated among higher-income clients, security infrastructure requirements, and regulatory overhead that new entrants may have underestimated. This parallel should be treated cautiously, however, since the psilocybin service market is smaller, younger, and structured differently from cannabis retail in ways that could limit how far the comparison extends.
The specific cost structure deserves attention, even if firm conclusions are hard to draw from three years of data. The $10,000 annual service center license fee, combined with OHA’s mandated security infrastructure, SB 303 outcome reporting obligations, and the overhead of professional facilitator staffing at a market where sessions typically cost between $1,000 and $5,000, appears to produce operating cost pressure that smaller-scale operators may struggle to sustain on thin margins. The equity applicants that OAR 333-333-1090’s equity program is designed to serve appear to be disproportionately represented among closures, though the tracker data available does not permit a fully confident causal account of why.
OHA’s funding position compounds the structural stress the program appears to be under. The program drew $3.1 million from Oregon’s general fund in 2023–25 with no legislative appropriation for 2025–27. OHA has indicated that the $10,000 annual service center fee may increase. For anyone modeling the economics of a service center, it may be worth treating a fee increase as a plausible per-location annual variable rather than a fixed, settled overhead item.
Two structural developments since the framework’s launch bear on this analysis. First, the two-year residency requirement for majority ownership of Oregon psilocybin businesses expired on January 1, 2025. Out-of-state investors may now hold majority interests in Oregon service centers directly, without the option-plus-49% structures that characterized early capitalization arrangements. This appears to remove one of the primary structural differences between Oregon psychedelic investment and standard multi-state cannabis investment, though how quickly capital markets will actually respond to that change is not yet clear. Second, SB 303 (2023, effective 2025) created a state-maintained client outcome data reporting requirement that is now generating an OHA administrative record of session outcomes, the long-term implications of which remain to be seen.
C. Colorado: The Developing Comparison Point
Colorado’s Natural Medicine Health Act, implemented through SB23-290 and DORA’s 4 CCR 755-1, licenses healing center facilitators under two distinct tracks: the Facilitator license (150-hour training) and the Clinical Facilitator license (requiring a secondary clinical license such as MD, psychologist, or licensed counselor). Facilitator licensing opened in December 2024; healing centers began operating in spring 2025, recently enough that comparisons to Oregon’s three-year record should be read as preliminary.
Colorado’s explicit Clinical Facilitator pathway permits a dual-licensed professional to draw on both bodies of training during sessions, a departure from Oregon’s harder separation of facilitation from clinical care. It is possible that a Colorado Clinical Facilitator could face both a facilitator standard and a clinical professional standard for the same conduct, while an Oregon dual-licensed facilitator would likely face only the facilitator standard, though this framing has not been tested in any reported dispute. SB25-297, effective 2026, requires Colorado healing centers to provide de-identified client data to the CDPHE beginning July 1, 2026, raising a discoverability question similar to the one SB 303 raises in Oregon, and one that neither state’s courts appear to have addressed yet.
III. What Cannabis May Have Gotten Right, and What Oregon Appears to Have Borrowed
Cannabis law developed, over two decades, a body of practical and regulatory knowledge that the psychedelic services industry appears to be inheriting, at least in part. Three elements that cannabis regulation arguably got right, and that Oregon’s framework seems to have incorporated, are worth examining.
License type separation and scope limitation
Cannabis regulatory frameworks, over time, came to treat license category as the primary tool for defining the scope of permitted activity, on the theory that scope ambiguity tends to generate regulatory violations and civil exposure. Oregon’s three-license structure, service center, facilitator, manufacturer, is more granular than many cannabis jurisdictions’ initial frameworks, and this granularity may reflect that lesson, though it is difficult to know how deliberately Oregon’s drafters drew on cannabis precedent versus arriving at a similar structure independently. OAR 333-333-1010(16)’s scope-of-practice definition functions as the jurisdictional boundary of a facilitator’s permitted conduct, not merely as descriptive guidance.
The operating agreement as a compliance instrument
Cannabis MSO practice developed the operating agreement as a primary vehicle for embedding regulatory compliance obligations into the governance of licensed entities. A similar structure appears applicable to Oregon psychedelic service centers. A service center operating agreement could, for instance, specify OAR compliance obligations, SB 303 documentation requirements, emergency response protocols under OAR 333-333-4700, and the boundary prohibitions of OAR 333-333-5120(7) and (10) as contractual obligations layered on top of the regulatory ones, though whether operators are actually doing this in practice is not something the available data confirms.
Data retention and litigation preparedness from day one
Cannabis litigation experience suggests that documentation practices established well before any dispute arises tend to become the foundation of a defense once a dispute does arise. For psychedelic service centers, this lesson may be amplified by SB 303’s reporting requirement, which creates a state-maintained record alongside a service center’s internal records, and by the absence of a clearly defined standard of care, which could make contemporaneous documentation of facilitator judgment calls unusually important evidence in any future negligence proceeding.
IV. What Cannabis May Have Gotten Wrong, and How Oregon Appears to Have Responded
Cannabis legalization is widely understood to have produced three structural difficulties: social equity programs that granted licenses without meaningful capital access, insurance markets that did not develop adequate professional liability products, and § 280E tax treatment that made cannabis businesses difficult to sustain under high regulatory overhead. Oregon’s framework appears to have addressed each of these with varying degrees of success, though “success” here is a tentative characterization given how early the program still is.
Social equity
Oregon’s OAR 333-333-1090 equity program provides technical assistance and fee reductions for qualifying applicants. It does not provide capital. The lesson cannabis regulation may offer, that equity licenses without equity capital risk being largely symbolic, appears, on this data, to be recurring in the psilocybin context as well. Service centers serving lower-income populations and equity applicants appear to be disproportionately represented among the roughly one-third that have closed, though again, the tracker data does not establish a firm causal link.
Insurance
The professional liability market for psilocybin facilitators appears to be developing but remains thin. General liability insurance, which OHA requires as a condition of service center licensure, covers bodily injury and property damage but typically excludes professional liability claims. Professional liability policies for facilitators appear to be emerging, though coverage terms seem inconsistent across carriers. This may leave a coverage gap around the contraindication screening, session management, and boundary violation liability categories that OAR 333-333-5120 creates, a gap that regulators or industry associations may want to examine more closely.
§ 280E divergence
The DEA’s April 2026 rescheduling action moved certain cannabis products from Schedule I to Schedule III, relieving qualifying cannabis operators from § 280E’s prohibition on business expense deductions. Psilocybin remains Schedule I. Psilocybin service centers accordingly remain fully subject to § 280E. This divergence appears likely to create a meaningful competitive asymmetry for any operator running both cannabis and psilocybin businesses within the same corporate family, since the cost structure, entity design, and capitalization considerations on the psilocybin side continue to operate under materially different tax treatment than the cannabis side.
This asymmetry may be worth particular attention from anyone structuring a multi-modality operation, since entity separation, cost allocation methodology, and intercompany arrangement design could affect how much of § 280E’s continued burden falls on the psilocybin operations specifically.
V. Six Areas Where the Framework’s Practical Operation Raises Open Questions
Six areas of the Measure 109 framework appear, on the current record, to raise practical questions that go beyond the statutory text itself. Each is discussed below with the governing ORS or OAR authority and a description of the open questions the framework leaves.
V.A Informed Consent and Scope Limitation
Oregon’s OAR 333-333-5040 mandates a specific informed consent document covering the nature of psilocybin services, risks, the non-medical character of services, client rights, and the facilitator’s scope limitations. The informed consent document functions both as a regulatory compliance instrument and, potentially, as an important evidentiary document in any future negligence claim, though its evidentiary weight in an actual dispute has not been tested.
The scope limitation described in the informed consent document may function as a service center’s first line of liability management, though this is an inference rather than a settled legal conclusion. ORS § 475A.305’s declaration that psilocybin services are not health care does not appear to eliminate liability outright; it may instead define its scope, without resolving how broadly that scope will be read. Informed consent documents that describe accurately what the service is, what a facilitator can and cannot do, and what a client should expect from integration may create a more defensible record than documents using therapeutic language inconsistent with OAR 333-333-1010(72)’s prohibition on the term “therapy,” though this too is an inference rather than a tested proposition, since no reported Oregon decision appears to have addressed the adequacy of a service center’s informed consent language.
V.B Professional Licensing Law
Facilitator licensing requirements differ meaningfully between Oregon and Colorado, and between the standard Facilitator track and Colorado’s Clinical Facilitator track. Oregon requires 120 hours of facilitator training approved by OHA, a practicum under supervision, and a passing score on a written examination. Annual renewal requires four hours of continuing facilitator education. Colorado requires 150 hours of training, a practicum, a written examination, and, for Clinical Facilitators, a current secondary clinical license in good standing.
As of Q3 2025, Oregon had issued 366 active facilitator licenses against a pool of approximately 23 to 25 operational service centers, a supply-demand imbalance that appears to be producing facilitator underemployment. A number of licensed facilitators appear to be working as gig workers without sustainable full-time placement, though the precise scale of this underemployment is difficult to establish from public data alone. This market reality may be relevant to anyone structuring a facilitator’s practice arrangement or advising on realistic income expectations in this field.
V.C SB 303 Data Reporting and Discoverability
Oregon Senate Bill 303 (2023), effective 2025, requires service centers to collect and submit to OHA client outcome data including numbers of clients served, adverse reactions, dosing averages, and denial reasons. This creates a state-maintained administrative record of session outcomes that could, in a future civil proceeding, become discoverable, though whether and how a court would treat such a record as discoverable has not, to date, been tested.
A service center’s SB 303 submissions may constitute a record that opposing counsel would seek in discovery in a hypothetical facilitator negligence case. This raises a question about whether SB 303 reporting practices are being kept consistent with underlying session records, reviewed with an eye to potential future litigation exposure before submission, and integrated into a service center’s broader records retention approach under OAR 333-333-4820, questions that individual service centers, and perhaps OHA itself, may want to consider.
Beyond SB 303, there is a further question about how the reporting requirement interacts with ORS § 475A.450’s client confidentiality protections. SB 303 requires submission of data to OHA; ORS § 475A.450 protects client information from disclosure. The two obligations are not necessarily in tension, SB 303 data may be de-identified, but the relationship between them does not appear to have been fully clarified in guidance or litigation.
V.D SSRI Exposure
Oregon’s service center framework does not exclude clients using selective serotonin reuptake inhibitors (SSRIs), and Psychedelic Alpha’s Q1 2025 data estimates that up to 80% of Oregon service center clients may be using SSRIs at the time of their session. The OAR rules appear to provide no specific guidance on SSRI-psilocybin interactions, and the OHA client information form does not appear to screen for SSRI use directly.
This may represent an unaddressed gap in the screening framework, though characterizing it definitively as a gap assumes that OHA has not addressed it through informal guidance not reflected in the public rules, a possibility that has not been ruled out here. If that gap exists as described, a facilitator who proceeds with an administration session for a client on a medication that interacts with psilocybin, where the screening process did not surface that use, could face professional negligence exposure that the framework’s disclaimer language may not fully foreclose, though it would likely be difficult to state with confidence how a court would resolve such a claim absent a defined standard of care. The standard-of-care question, whether a reasonable facilitator would have asked about SSRI use, would likely be answered, in any actual dispute, by expert testimony about what facilitator training programs currently teach. This may be an area regulators want to examine, since an explicit SSRI inquiry added to the intake process, documented as part of the informed consent discussion, could reduce ambiguity in this space, though that is a suggestion rather than a claim about what current facilitators are or are not doing.
V.E Section 280E Divergence
Section 280E divergence appears to warrant continued attention for existing psychedelic operations. As cannabis operators gain the ability to deduct ordinary business expenses post-rescheduling, psilocybin service centers remain subject to § 280E’s full prohibition. The competitive asymmetry for multi-modality operators, those running cannabis and psilocybin businesses in the same corporate family, appears significant, though its precise magnitude would depend on the specific cost structure of each operation. Entity structure, cost allocation methodology, and intercompany arrangements may be relevant considerations for minimizing § 280E’s application to the psilocybin side without inadvertently drawing the cannabis-side deductibility improvements into question through shared operations.
V.F Healthcare Liability Insurance
The insurance market for psychedelic service centers appears to be developing, and coverage gaps seem real, though the scope of those gaps is difficult to quantify from public information. General liability covers bodily injury and property damage. It does not appear to cover professional liability claims for negligent facilitation, failure to recognize a contraindication, or session management failures. The specific liability categories created by OAR 333-333-5120, contraindication screening failure, session management failure, boundary violation, appear to call for professional liability (errors and omissions) coverage that is emerging but not yet standardized across carriers. This may be an area where coverage terms deserve closer examination against these specific categories, since exclusions in current policies could leave service centers exposed on precisely the claims that seem most likely to arise.
VI. Conclusion: A Developing Framework, an Unsettled Market
Oregon’s program data as of early 2026 offers the industry’s first real-world test of the service center model at scale, though “test” may overstate how conclusive three years of data can be. The results appear mixed in a way that resists a single verdict: the safety record looks strong on the available numbers (six adverse events among 1,509 clients in Q1 2025), demand appears consistent among clients who can afford sessions, and the framework’s non-clinical structure seems, on this record, to have functioned largely as designed. At the same time, approximately one-third of service centers have closed amid cost pressures, OHA appears to face a funding shortfall, and the facilitator pipeline seems to be producing more licensed professionals than the market can currently absorb.
Whether this record should be read as an early success story with rough edges, or as a cautionary account of a well-designed framework meeting insufficient demand and funding, may not be answerable yet. The data may support a more cautious assessment of the program’s early performance than either framing would suggest, and it is probably too early to characterize Oregon’s experience as a definitive failure or a settled success.
For regulators and legislators considering similar frameworks, in Oregon’s own next legislative session, in Colorado, or in other states weighing psychedelic service models, the following observations may be worth considering:
- Oregon’s Legislature may wish to revisit dedicated program funding for 2025–27 and beyond, given that OHA’s reliance on general fund draws and a possible fee increase suggests the current funding model may not be durable without legislative attention.
- OHA and comparable agencies elsewhere could consider issuing explicit guidance on SSRI and other medication screening, since the current framework does not appear to address a documented interaction risk directly, and clearer guidance might reduce ambiguity for facilitators and service centers alike.
- Regulators designing equity provisions in future psychedelic frameworks may want to consider pairing technical assistance and fee reductions with actual capital access mechanisms, given that Oregon’s equity applicants appear disproportionately represented among closures.
- State insurance regulators and industry bodies might consider working with carriers to develop standardized professional liability products specific to the contraindication-screening, session-management, and boundary-violation liability categories that frameworks like Oregon’s create, since the current insurance market appears to leave gaps in exactly these areas.
- Legislatures adopting SB 303-style reporting requirements may want to clarify, in the statute or accompanying guidance, how such reporting interacts with client confidentiality protections and civil discovery, since this relationship does not appear to have been fully resolved in either Oregon or Colorado’s frameworks.
- States considering their own facilitator licensing programs may benefit from modeling projected facilitator supply against realistic service center capacity, given the apparent imbalance in Oregon between licensed facilitators and available placements.
Oregon’s framework remains, on the available evidence, a serious and carefully constructed piece of regulatory design. The market built on top of it, three years in, appears considerably more fragile than the statute and rules alone would suggest, a distinction that may matter as other jurisdictions decide how closely to follow the Oregon model.
Endnotes
- ORS §§ 475A.100–475A.500 (Oregon Psilocybin Services Act); OAR 333-333-1010 et seq. (OHA implementing rules); Oregon Health Authority, Oregon Psilocybin Services, https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Oregon-Psilocybin-Services.aspx (last visited June 2026); Psychedelic Alpha, The Oregon Psilocybin Services Tracker (updated June 2026), https://psychedelicalpha.com/data/the-oregon-psilocybin-services-tracker (documenting 12 closures of 35 licensed service centers through Q3 2025; 366 active facilitator licenses; Q1 2025 adverse event rate of 6 per 1,509 clients; estimating up to 80% of clients may be using SSRIs at time of session).
- ORS § 475A.305 (“a psilocybin service center is not a health care facility subject to ORS chapter 441”); OAR 333-333-1010(72) (prohibiting use of term “therapy”); OAR 333-333-5130 (prohibiting facilitator diagnosis or treatment); OAR 333-333-5120(1) (duty to put clients’ interest above facilitator’s own; standard of care of other reasonable facilitators under similar circumstances); Willamette Week, Oregon’s Psychedelic Service Centers Are Closing Amid High Costs and Tough Regulation (June 3, 2025), https://www.wweek.com/news/2025/06/03/oregons-psychedelic-service-centers-are-closing-amid-high-costs-and-tough-regulation.
- OPB, A third of Oregon’s licensed psilocybin service centers have closed (Jan. 22, 2026), https://www.opb.org/article/2026/01/22/think-out-loud-oregon-licensed-psilocybin; Psychedelic Alpha Tracker, supra note 1 (documenting closure data); OAR 333-333-1090 (equity program requirements, technical assistance, fee reductions).
- SB23-290, Colo. 74th Gen. Assemb. (2023) (Natural Medicine Health Act); 4 CCR 755-1 (DORA implementing rules); SB25-297, Colo. 75th Gen. Assemb. (2025) (de-identified client data reporting to CDPHE, effective July 1, 2026); Or. S.B. 303 (2023) (service center client outcome data reporting to OHA, effective 2025), https://olis.oregonlegislature.gov/liz/2023R1/Measures/Overview/SB303.